This post was originally published on this site

Press release content from Business Wire. The AP news staff was not involved in its creation.

SAN DIEGO–(BUSINESS WIRE)–Apr 1, 2021–

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 49,040 shares of its common stock to eight new employees. These inducement stock options have a grant date of March 31, 2021, and were granted as inducements material to the new employees entering into employment with Biocept in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement stock options have an exercise price of $5.09 per share, the closing price of Biocept’s common stock on March 31, 2021 (the grant date), are non-qualified stock options, have a ten-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the remaining 75% of the shares vesting in equal monthly installments over the following 36 months, subject to the new employee’s continued service with Biocept through the applicable vesting dates. The inducement stock options are subject to the terms and conditions of Biocept’s Amended and Restated 2013 Equity Incentive Plan.

ADVERTISEMENT

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept is developing and commercializing its cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system. The Company’s CSF assay identifies molecular targets for clinical decision making and provides quantitative information for monitoring treatment response. Biocept’s patented Target Selector™ technology platform captures and analyzes tumor-associated molecular markers in both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) with higher sensitivity and specificity than most commercial assays. Additionally, Biocept is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For additional information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20210401005905/en/

CONTACT: Investor Contact:

LHA Investor Relations

Jody Cain

Jcain@lhai.com

310-691-7100

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: OTHER HEALTH HEALTH SCIENCE OTHER SCIENCE ONCOLOGY

SOURCE: Biocept, Inc.

Copyright Business Wire 2021.

PUB: 04/01/2021 05:00 PM/DISC: 04/01/2021 05:01 PM

http://www.businesswire.com/news/home/20210401005905/en